BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dupixent (dupilumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dupixent (dupilumab)\, from ClinicalTrial
 s.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06389136-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06389136)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: A S
 tudy of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic 
 Dermatitis and Inadequate Response to Dupilumab\nEstimated primary complet
 ion: November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/d
 upilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06389136
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06088771-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dupixent (dupilumab): Phase 1/2 readout est. (NCT06088771)
DESCRIPTION:Dupixent (dupilumab)\, phase 1/2.\nStudy: Neoadjuvant Dupilumab
  and Cemiplimab in Patients With Early-stage Resectable NSCLC\nEstimated p
 rimary completion: 1 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06088771
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06477653-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT06477653)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Dupilumab as Add-On The
 rapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosi
 nophil-Depleting Biologic Agents\nEstimated primary completion: 30 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0647765
 3
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05347771-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT05347771)
DESCRIPTION:Dupixent (dupilumab)\, phase 2\, Asthma.\nStudy: Prevention of 
 Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents\nEs
 timated primary completion: 31 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05347771
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03694158-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT03694158)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Investigating 
 Dupilumab's Effect in Asthma by Genotype\nEstimated primary completion: Ja
 nuary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab
 #upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT036
 94158
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05535738-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:Dupixent (dupilumab): Phase 2/3 readout est. (NCT05535738)
DESCRIPTION:Dupixent (dupilumab)\, phase 2/3.\nStudy: Using a Contact Derma
 titis Model With Biologic Medications to Study Skin Inflammation\nEstimate
 d primary completion: 1 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05535738
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07905547-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270207
DTEND;VALUE=DATE:20270208
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT07905547)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Atopic Dermatitis.\nStudy: A S
 tudy to Investigate Dupixent/ Dupilumab in Adult Indian Participants With 
 Moderate-to-severe Atopic Dermatitis\nEstimated primary completion: 7 Febr
 uary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0790
 5547
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06637306-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270310
DTEND;VALUE=DATE:20270311
SUMMARY:Dupixent (dupilumab): Phase 1 readout est. (NCT06637306)
DESCRIPTION:Dupixent (dupilumab)\, phase 1.\nStudy: Neoadjuvant Dupilumab\,
  Pembrolizumab\, Paclitaxel\, and Carboplatin in Locally Advanced Triple N
 egative Breast Cancer\nEstimated primary completion: 10 March 2027. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06637306
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05097287-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270316
DTEND;VALUE=DATE:20270317
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT05097287)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Study Assessin
 g the Long-term Effect of Dupilumab on Prevention of Lung Function Decline
  in Adult Patients With Uncontrolled Moderate to Severe Asthma\nEstimated 
 primary completion: 16 March 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05097287
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06572228-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270424
DTEND;VALUE=DATE:20270425
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT06572228)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Efficacy of Du
 pilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agoni
 st (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA i
 n Adolescent and Adult Patients With Uncontrolled Asthma\nEstimated primar
 y completion: 24 April 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT06572228
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05983068-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270429
DTEND;VALUE=DATE:20270430
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT05983068)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Atopic Dermatitis.\nStudy: A S
 tudy of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatri
 c Participants With Atopic Dermatitis\nEstimated primary completion: 29 Ap
 ril 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05983
 068
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05042258-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT05042258)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Atopic Dermatitis.\nStudy: Usi
 ng Dupilumab to Improve Circadian Function\, Sleep and Pruritus in Childre
 n With Moderate/Severe Atopic Dermatitis\nEstimated primary completion: Ju
 ne 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT050422
 58
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05263206-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270602
DTEND;VALUE=DATE:20270603
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT05263206)
DESCRIPTION:Dupixent (dupilumab)\, phase 3.\nStudy: Efficacy and Safety of 
 Subcutaneous Dupilumab for the Treatment of Adult Participants With Chroni
 c Pruritus of Unknown Origin (CPUO) (LIBERTY-CPUO-CHIC)\nEstimated primary
  completion: 2 June 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05263206
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06385236-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT06385236)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Leveraging Pha
 rmacogenomics in Asthma for Predication\, Mechanism and Endotyping\nEstima
 ted primary completion: 30 June 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06385236
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05268107-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT05268107)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Atopic Dermatitis.\nStudy: Eth
 nic Differences in Mechanisms of Action of Dupilumab\nEstimated primary co
 mpletion: July 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT05268107
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06293053-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06293053)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Prurigo Nodularis.\nStudy: A S
 tudy to Investigate the Pharmacokinetics and Safety of Dupilumab in Partic
 ipants ≥6 Months to <18 Years of Age With Prurigo Nodularis\nEstimated p
 rimary completion: 28 October 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06293053
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05551793-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT05551793)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Regeneron AA Multicente
 r (Dupilumab)\nEstimated primary completion: 30 November 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT05551793
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07358234-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dupixent (dupilumab): Phase 1 readout est. (NCT07358234)
DESCRIPTION:Dupixent (dupilumab)\, phase 1\, Eosinophilic Esophagitis.\nStu
 dy: Comparison of Eohilia With Dupixent on Esophagus Diameter in Patients 
 With Eosinophilic Esophagitis.\nEstimated primary completion: December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07358234
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04743791-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT04743791)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Measuring the 
 Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects W
 ith Moderate to Severe Asthma\nEstimated primary completion: December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT04743791
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06743581-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dupixent (dupilumab): Phase na readout est. (NCT06743581)
DESCRIPTION:Dupixent (dupilumab)\, phase na.\nStudy: Study of Neoadjuvant C
 emiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer\nEstimat
 ed primary completion: December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06743581
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06226610-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT06226610)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Dupixent in Adults With
  Refractory Post-Burn Pruritus in an Ambulatory Clinic\nEstimated primary 
 completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06226610
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06818019-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT06818019)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Asthma.\nStudy: Withdrawal of 
 Dupilumab in Severe Asthma\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06818019
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05858619-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280201
DTEND;VALUE=DATE:20280202
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT05858619)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Atopic Dermatitis.\nStudy: Mol
 ecular Signatures of Cutaneous Dupilumab Response\nEstimated primary compl
 etion: 1 February 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT05858619
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07091175-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280228
DTEND;VALUE=DATE:20280229
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT07091175)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Dupilumab Therapy in Ne
 phrotic Syndrome in Children\nEstimated primary completion: 28 February 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07091175
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07919899-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280502
DTEND;VALUE=DATE:20280503
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07919899)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Atopic Dermatitis.\nStudy: Pha
 rmacokinetics\, Immunogenicity and Safety of Subcutaneous Dupilumab and Be
 rahyaluronidase Alfa (ALT-B4) Coformulation\nEstimated primary completion:
  2 May 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupiluma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 919899
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07112378-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280619
DTEND;VALUE=DATE:20280620
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07112378)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Eosinophilic Esophagitis.\nStu
 dy: A Study of Dupilumab in Small Children With an Allergic Condition of t
 he Esophagus (Food Pipe): Eosinophilic Esophagitis\nEstimated primary comp
 letion: 19 June 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07112378
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07587658-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20280730
DTEND;VALUE=DATE:20280731
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT07587658)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Chronic Obstructive Pulmonary 
 Disease.\nStudy: This After Market Study is Seeing if Dupilumab Plus Usual
  Standard of Care (SOC) is Better Than Usual Care Alone for Adult Particip
 ants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up 
 Requiring Hospitalization\nEstimated primary completion: 30 July 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07587658
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07908563-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT07908563)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Dupilumab in Major Depr
 essive Disorder\nEstimated primary completion: December 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07908563
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06191315-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281221
DTEND;VALUE=DATE:20281222
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT06191315)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: Efficacy and S
 afety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Whee
 ze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)\nEstimated primary completi
 on: 21 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /dupilumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT06191315
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07053423-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281223
DTEND;VALUE=DATE:20281224
SUMMARY:Dupixent (dupilumab): Phase 4 readout est. (NCT07053423)
DESCRIPTION:Dupixent (dupilumab)\, phase 4\, Chronic Obstructive Pulmonary 
 Disease.\nStudy: A Study to Investigate Airway Inflammation With Dupilumab
  Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obs
 tructive Pulmonary Disease.\nEstimated primary completion: 23 December 202
 8. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07053423
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07277322-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Dupixent (dupilumab): Phase 1/2 readout est. (NCT07277322)
DESCRIPTION:Dupixent (dupilumab)\, phase 1/2.\nStudy: Neoadjuvant Dupilumab
  and Toripalimab in MSS CRC Subjects With Resectable Liver Metastases\nEst
 imated primary completion: 31 December 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT07277322
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07309614-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20290131
DTEND;VALUE=DATE:20290201
SUMMARY:Dupixent (dupilumab): Phase 3 readout est. (NCT07309614)
DESCRIPTION:Dupixent (dupilumab)\, phase 3\, Asthma.\nStudy: A Study Assess
 ing the Effect of Dupilumab on Inducing Clinical Remission in Asthma\nEsti
 mated primary completion: January 2029. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT07309614
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05866562-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Dupixent (dupilumab): Phase 2 readout est. (NCT05866562)
DESCRIPTION:Dupixent (dupilumab)\, phase 2.\nStudy: Dupilumab in the Treatm
 ent of Pediatric Alopecia Areata\nEstimated primary completion: 31 March 2
 029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/dupilumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT05866562
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05649098-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20310630
DTEND;VALUE=DATE:20310701
SUMMARY:Dupixent (dupilumab): Phase 1 readout est. (NCT05649098)
DESCRIPTION:Dupixent (dupilumab)\, phase 1.\nStudy: Repurposing Dupilumab f
 or Management of Pruritic Genetic Inflammatory Skin Disorders\nEstimated p
 rimary completion: 30 June 2031. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/dupilumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT05649098
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06501807-1356@assetmemo.bio
DTSTAMP:20261121T005013Z
DTSTART;VALUE=DATE:20340902
DTEND;VALUE=DATE:20340903
SUMMARY:Dupixent (dupilumab): Phase na readout est. (NCT06501807)
DESCRIPTION:Dupixent (dupilumab)\, phase na.\nStudy: BIOlogics in Severe Na
 sal POlyposis SurvEy.: a French Registry\nEstimated primary completion: 2 
 September 2034. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/dupil
 umab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T06501807
URL:https://assetmemo.bio/drug/dupilumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
